Canaan Partners

OpenArt is a platform dedicated to AI art enthusiasts, allowing users to create and modify images using advanced AI technologies. The startup, founded by ex-Googlers, aims to democratize art creation through generative AI.

The RealReal is a luxury resale and consignment platform that allows users to buy and sell designer clothes, bags, shoes, and jewelry.

Day One Biopharmaceuticals is dedicated to developing targeted cancer therapies for children and adults, focusing on innovative drug development to provide new treatment options for patients in need.

IDEAYA is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics for cancer, particularly through synthetic lethality and antibody-drug conjugates.

Protagonist Therapeutics is focused on innovation in drug discovery and development, particularly in the areas of peptide-based therapeutics for various diseases.

Synthekine is a biotechnology company focused on discovering, developing, and commercializing selective cytokine therapeutics to treat cancer and autoimmune diseases.

Nocion Therapeutics is a biopharmaceutical company developing 'nocions'—a new kind of therapy that selectively affects actively firing nociceptors to provide targeted relief for conditions such as cough, itch, pain, and inflammation.

Arrakis Therapeutics is pioneering a new class of genetic medicines known as RNA-targeted small molecules (rSMs), aiming to unlock new biology for patients by creating oral medicines that target RNA.

Glooko is a leading diabetes management platform that simplifies diabetes data management for healthcare providers and individuals living with diabetes. It integrates data from over 200 diabetes and health monitoring devices, enhances clinical workflows, and improves health outcomes through personalized, intelligent, connected care solutions.

Berkshire Grey provides AI-powered robotic solutions for logistics and supply chain operations, including robotic picking, package sortation, and trailer unloading.

Hermeus is a high-speed aircraft manufacturer focused on the rapid design, build, and test of high-Mach and hypersonic aircraft for the national interest.

MBX Capital is a venture capital fund with a "deep health" thesis that treats health as a systems problem. They invest across biology, chemistry, AI/ML, robotics, and clinical medicine to back companies addressing root causes of environmental health and healthcare infrastructure challenges. The fund makes $1–2.5M first checks targeting ≥5% equity and operates with a private "Atom Network" of hundreds of scientific and clinical experts who help source and vet investments.

Solo-GP venture capital fund founded and managed entirely by Dr. Ling Wong, an MIT-trained chemical engineer and biologist with a Harvard PhD who invented the world's first inhaled tuberculosis vaccine. The fund writes checks from $500K to $50M across seed through growth stages, backing breakout companies like Slack (acquired by Salesforce for $27.7B), Guardant Health (IPO), and Anacor (acquired by Pfizer for $5.2B) while co-investing alongside top-tier firms like Andreessen Horowitz and Sequoia.

F-Prime Capital is one of the few large global VC firms that has built over 30 companies from scratch rather than just backing existing startups, drawing on Fidelity's resources to combine deep healthcare and technology expertise with a structured company-formation engine that pulls together academic founders across multiple geographies. The firm operates with sister fund Eight Roads to create one of the broadest cross-border VC footprints, systematically syndicating ideas across the U.S., Europe, China, Japan, India, and Israel while maintaining a distinctive "technical-risk-yes, regulatory-risk-no" filter that avoids heavy regulatory categories like broad antibiotics in favor of rare diseases and gene therapy where FDA pathways are clearer.

Early-stage investor in advanced tech and healthcare that funds companies with at least one female founder, focusing on STEM startups with female executives.